黑色素瘤中免疫检查点抑制剂反应的预测生物标志物。
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
作者信息
Nebhan Caroline A, Johnson Douglas B
机构信息
Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, USA.
出版信息
Expert Rev Anticancer Ther. 2020 Feb;20(2):137-145. doi: 10.1080/14737140.2020.1724539. Epub 2020 Feb 5.
Abstract
: Advanced melanoma has recently been transformed by the advent of immune checkpoint inhibitors. These agents have altered the prognosis of this disease from a median survival of <1 year to recent data showing a 5-year survival surpassing 50%. Combination regimens combining PD-1 and CTLA-4 blockade are associated with superior response and progression-free survival at the cost of increased toxicities.: In this review, we discuss the clinical and investigational utility of predictive biomarkers of immune checkpoint inhibitor treatment in melanoma. Topics include tumor-intrinsic biomarkers, tumor microenvironment biomarkers, and host characteristic biomarkers. We also discuss biomarkers of immune-related adverse events and how biomarkers may be used to personalize the selection of immune checkpoint inhibition in patients.: The decisions confronting oncologists when choosing treatment are increasing in complexity. Biomarkers may aid in these treatment decisions and are growing in importance.
摘要
晚期黑色素瘤最近因免疫检查点抑制剂的出现而发生了改变。这些药物已将这种疾病的预后从中位生存期小于1年转变为近期数据显示的5年生存率超过50%。联合使用PD-1和CTLA-4阻断的联合方案与更高的缓解率和无进展生存期相关，但代价是毒性增加。
在本综述中，我们讨论了黑色素瘤中免疫检查点抑制剂治疗预测生物标志物的临床和研究效用。主题包括肿瘤内在生物标志物、肿瘤微环境生物标志物和宿主特征生物标志物。我们还讨论了免疫相关不良事件的生物标志物，以及生物标志物如何用于个性化选择患者的免疫检查点抑制治疗。
肿瘤学家在选择治疗方案时面临的决策越来越复杂。生物标志物可能有助于这些治疗决策，并且其重要性日益增加。
相似文献
1
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.黑色素瘤中免疫检查点抑制剂反应的预测生物标志物。
Expert Rev Anticancer Ther. 2020 Feb;20(2):137-145. doi: 10.1080/14737140.2020.1724539. Epub 2020 Feb 5.
2
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.将 BRAF/MEK 抑制剂与免疫疗法联合用于治疗转移性黑色素瘤。
Am J Clin Dermatol. 2021 May;22(3):301-314. doi: 10.1007/s40257-021-00593-9. Epub 2021 Mar 25.
3
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.联合 PD-1、BRAF 和 MEK 抑制治疗晚期 BRAF 突变型黑色素瘤：COMBI-i 的安全性预试验和生物标志物队列。
Nat Med. 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5.
4
Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?BRAF 突变型黑色素瘤接受联合靶向治疗或免疫检查点阻断治疗的长期结局：我们是否正在接近真正的治愈？
Am J Clin Dermatol. 2020 Aug;21(4):493-504. doi: 10.1007/s40257-020-00509-z.
5
Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.通过单克隆抗体 D16F7 靶向血管内皮生长因子受体-1 以提高免疫检查点抑制剂对皮肤黑色素瘤的活性。
Pharmacol Res. 2020 Sep;159:104957. doi: 10.1016/j.phrs.2020.104957. Epub 2020 May 30.
6
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.新兴的免疫检查点抑制剂治疗肝细胞癌。
Expert Opin Emerg Drugs. 2021 Mar;26(1):39-52. doi: 10.1080/14728214.2021.1902503. Epub 2021 Mar 19.
7
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.接受检查点阻断治疗的黑色素瘤患者转移灶切除术的生存结果分类。
Ann Surg Oncol. 2020 Apr;27(4):1180-1188. doi: 10.1245/s10434-019-08099-9. Epub 2019 Dec 17.
8
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.黑色素瘤患者的免疫检查点抑制剂诱导的白癜风：专家意见。
Expert Opin Drug Saf. 2021 Aug;20(8):883-888. doi: 10.1080/14740338.2021.1915279. Epub 2021 Apr 27.
9
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.免疫检查点抑制剂（抗CTLA-4、抗PD-1）单药治疗与免疫检查点抑制剂（抗CTLA-4、抗PD-1）联合抗RANKL地诺单抗治疗恶性黑色素瘤的疗效比较：三级医疗中心的回顾性分析
Melanoma Res. 2018 Aug;28(4):341-347. doi: 10.1097/CMR.0000000000000459.
10
Cutaneous melanoma and the immunotherapy revolution (Review).皮肤黑色素瘤与免疫治疗革命（综述）。
Int J Oncol. 2020 Sep;57(3):609-618. doi: 10.3892/ijo.2020.5088. Epub 2020 Jun 25.
引用本文的文献
1
Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations.亚洲人群黑色素瘤分子研究与治疗的最新进展
Int J Mol Sci. 2025 Jun 3;26(11):5370. doi: 10.3390/ijms26115370.
2
Skin Photodamage and Melanomagenesis: A Comprehensive Review.皮肤光损伤与黑色素瘤发生：综述
Cancers (Basel). 2025 May 26;17(11):1784. doi: 10.3390/cancers17111784.
3
Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review).晚期肝细胞癌中放射治疗与免疫检查点抑制剂的联合应用：当前证据与未来前景的系统评价（综述）
Oncol Lett. 2025 May 14;30(1):342. doi: 10.3892/ol.2025.15088. eCollection 2025 Jul.
4
The role of kinesin superfamily proteins in hepatocellular carcinoma.驱动蛋白超家族蛋白在肝细胞癌中的作用。
Med Oncol. 2024 Oct 14;41(11):271. doi: 10.1007/s12032-024-02497-0.
5
Molecular Susceptibility and Treatment Challenges in Melanoma.黑色素瘤的分子易感性和治疗挑战。
Cells. 2024 Aug 20;13(16):1383. doi: 10.3390/cells13161383.
6
Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.关于黑色素瘤免疫治疗耐药性以及潜在预测性和预后生物标志物的当前知识。
Cancer Drug Resist. 2024 May 13;7:17. doi: 10.20517/cdr.2023.150. eCollection 2024.
7
Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence.利用人工智能细化基于突变组学的个体化黑色素瘤免疫治疗。
Eur J Med Res. 2024 Jan 5;29(1):25. doi: 10.1186/s40001-023-01625-2.
8
Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.接受程序性细胞死亡蛋白 PD-1 阻滞剂治疗的黑色素瘤患者外周血中免疫检查点成分 PD-1/PD-L1/B7-H3、CD314/ULBP1 和 HLA-G 的可溶性形式的动态变化。
Bull Exp Biol Med. 2023 Aug;175(4):481-486. doi: 10.1007/s10517-023-05891-2. Epub 2023 Sep 29.
9
TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.TUBA1C 是一种潜在的新的预后生物标志物，通过调节细胞周期促进膀胱尿路上皮癌的进展。
BMC Cancer. 2023 Aug 1;23(1):716. doi: 10.1186/s12885-023-11209-2.
10
Updates in toxicities associated with immune checkpoint inhibitors.免疫检查点抑制剂相关毒性的最新进展。
Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1117-1129. doi: 10.1080/1744666X.2023.2221434. Epub 2023 Jun 5.
本文引用的文献
1
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.先前抗生素治疗与癌症患者免疫检查点抑制剂治疗的生存和应答的相关性。
JAMA Oncol. 2019 Dec 1;5(12):1774-1778. doi: 10.1001/jamaoncol.2019.2785.
2
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.程序性死亡受体 1（PD-1）阻断治疗的癌症患者中微卫星不稳定性和高肿瘤突变负荷的无创检测
Clin Cancer Res. 2019 Dec 1;25(23):7024-7034. doi: 10.1158/1078-0432.CCR-19-1372. Epub 2019 Sep 10.
3
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity.应激-糖皮质激素-TSC22D3 轴损害治疗诱导的抗肿瘤免疫。
Nat Med. 2019 Sep;25(9):1428-1441. doi: 10.1038/s41591-019-0566-4. Epub 2019 Sep 9.
4
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.免疫治疗下黑色素瘤反应的蛋白质组学研究揭示了线粒体的依赖性。
Cell. 2019 Sep 19;179(1):236-250.e18. doi: 10.1016/j.cell.2019.08.012. Epub 2019 Sep 5.
5
A case report of clonal EBV-like memory CD4 T cell activation in fatal checkpoint inhibitor-induced encephalitis.致命性免疫检查点抑制剂诱导性脑炎中克隆性 EBV 样记忆 CD4 T 细胞激活的病例报告。
Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.
6
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.达拉非尼联合曲美替尼治疗转移性黑色素瘤的 5 年结果。
N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
7
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.皮肤黑色素瘤临床实践指南（第 2 版）.2019，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.
8
Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.抗 PD-1 治疗对转移性黑色素瘤患者疗效的临床相关性分析。
J Immunother. 2019 Jul-Aug;42(6):221-227. doi: 10.1097/CJI.0000000000000258.
9
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负荷以及纳武利尤单抗单药治疗及联合伊匹木单抗治疗小细胞肺癌的疗效
Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011.
10
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.KEYNOTE-001 研究中接受派姆单抗治疗的晚期黑色素瘤患者的 5 年生存结果。
Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.
Zotero 插件